IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Obermeyer Wealth Partners

Obermeyer Wealth Partners cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,593 shares of the company's stock after selling 742 shares during the period. Obermeyer Wealth Partners' holdings in IDEXX Laboratories were worth $1,072,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IDXX. Geode Capital Management LLC boosted its holdings in IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after purchasing an additional 37,734 shares during the last quarter. Bamco Inc. NY raised its position in shares of IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after purchasing an additional 82,264 shares in the last quarter. Invesco Ltd. boosted its stake in shares of IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock valued at $479,999,000 after buying an additional 74,324 shares during the last quarter. Norges Bank acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $412,258,000. Finally, Northern Trust Corp increased its stake in shares of IDEXX Laboratories by 18.6% in the fourth quarter. Northern Trust Corp now owns 912,874 shares of the company's stock worth $377,419,000 after buying an additional 143,369 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on IDXX shares. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a research note on Monday, April 14th. Morgan Stanley upped their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Finally, Piper Sandler upped their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $524.75.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded up $6.11 during trading hours on Friday, hitting $518.10. The company had a trading volume of 524,927 shares, compared to its average volume of 648,919. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a market cap of $41.67 billion, a P/E ratio of 48.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $545.43. The business has a fifty day simple moving average of $429.46 and a 200-day simple moving average of $430.94.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same period in the previous year, the business posted $2.71 EPS. IDEXX Laboratories's revenue was up 3.6% on a year-over-year basis. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.